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httpcense.Abstract Background: Pulmonary arterial hypertension is a newly recognized disease in patients
with renal disease. In a recent review, the prevalence of PHT in ESRD patients was reported to be
around 40–50%.
Aim of the work: To evaluate the prevalence of primary pulmonary hypertension among CKD
patients on and without dialysis and to compare clinical, hemodynamic, and metabolic variables
among patients with and without PH to search for possible etiologic factors.
Patients and methods: Our study included 99 CKD patients; 65 patients on hemodialysis, 12 on
peritoneal dialysis and 22 on conservative management. Detailed medical history, examination, and
complete laboratory investigations were obtained. Systolic PAP, EF% and cardiac output were
evaluated by Doppler echocardiography and AVF ﬂow by Doppler ultrasound.isease; CKD, chronic kidney
tension
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762 M.M. Emara et al.Results: A high prevalence of pulmonary hypertension was demonstrated among 27 patients
(41.53%) receiving long-term hemodialysis with a mean systolic PAP of 49.33 ± 9.18 mmHg; as
well as in two patients (16.66%) receiving peritoneal dialysis 43 ± 1.41 mmHg, and in ﬁve patients
((22.72%) receiving conservative management 44.8 ± 5.89 mmHg.
Conclusion: This study demonstrated a high prevalence of pulmonary hypertension among
patients with CKD on and without dialysis. The prevalence was highest among patients with ESRD
receiving long-term hemodialysis (41.53%) especially in patients with older age, longer duration of
dialysis treatment, higher AV ﬁstula ﬂow, cardiac output.
ª 2013 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V.Open access under CC BY-NC-ND license.Introduction
Pulmonary hypertension (PHT) is a progressive disorder com-
plicating heart, lung, or systemic diseases, with increased mor-
bidity and mortality regardless of its etiology [1]. Pulmonary
arterial hypertension (PAH) is a newly recognized disease in
patients with renal disease [2]. In a recent review, the preva-
lence of PHT in ESRD patients was reported to be around
40–50% [3]. Pulmonary hypertension, deﬁned as systolic pul-
monary artery pressure (SPAP) > 35 mmHg at rest as esti-
mated by Doppler echocardiography, has been repeatedly
reported in patients with chronic kidney disease, both predial-
ysis and during regular renal replacement therapy, with a high
but variable prevalence [4,5]. Its presence has been recently
suggested to be associated with a worse outcome [6]. A number
of causative factors have been related to this pathological ﬁnd-
ing: pulmonary artery calciﬁcations secondary to hyperpara-
thyroidism [5]; and hemodynamic modiﬁcations related to
the creation of an arteriovenous ﬁstula (AVF), caused by a re-
duced ability of pulmonary vessels to accommodate the AV ac-
cess-mediated elevated cardiac output, possibly because of a
derangement of nitric oxide–endothelin metabolism [6] but
its pathogenesis has not been completely elucidated.
Patients and methods
Our-cross-sectional and retrospective study included a total of
99 CKD patients who were followed up at nephrology center
of King Fahd hospital, Al-Madinah Al-Munawarah, the
Kingdom of Saudi Arabia at the period between January
2010 and December 2011. They were divided into three groups;
group I involved 65 patients (34males, and 31 females with a
mean age 45.72 ± 7.83 years) who were maintained on long-
term regular hemodialysis therapy via arteriovenous ﬁstulas
(38 radial and 27 brachial AVF) three times per week in 4-h
sessions, group II included 12 patients (7 males, and 5 females
with a mean age 46.08 ± 3.84 years) on continuous ambula-
tory peritoneal dialysis and group III included 22 patients
(13 males, and 9 females with a mean age 45.45 ± 3.77 years)
on conservative management. Diabetic nephropathy was the
commonest cause of uremia (n= 40), then hypertensive
nephropathy (n= 31), Glomerulonephritis (n= 16), chronic
pyelonephritis (n= 6), cystic renal disease (n= 4), whereas
two patients had undetermined renal diagnosis. All patients in-
cluded in this study underwent the following:
(1) A detailed clinical examination including age; sex; smok-
ing habits; associated comorbidity particularly diabetesmellitus and hypertension; age at time of CKD, etiology
of renal failure, duration of dialysis treatment, and
access location of AVF [brachial or radial].
(2) Laboratory investigation included levels of hemoglobin,
hematocrit, blood urea nitrogen, serum creatinine,
serum bicarbonate, serum calcium, phosphorus, para-
thyroid hormone level. Average levels measured at least
twice in the study period were calculated.
(3) Transthoracic Doppler echocardiography: Every patient
underwent a complete two-dimensional and Doppler
echocardiography study on the day post dialysis within
4 h after completion of dialysis when the patient had
reached the ‘‘dry weight’’ prescribed by nephrologists
on the clinical examination including BP and weight in
order to avoid overestimation of PAP due to volume
overload. In PD patients there was no such speciﬁcation.
One experienced cardiologist performed all examina-
tions using an Acuson Sequoia, 512 (Mountain View,
CA, USA) ultrasound machine. The results of transtho-
racic Doppler echocardiography were used to determine
the pulmonary artery pressure (PAP), left ventricular
function, ejection fraction, and cardiac output.
Systolic PAP: A tricuspid regurgitation systolic jet was re-
corded from the parasternal or apical window with the contin-
uous-wave Doppler echocardiography probe. Systolic right
ventricular (or pulmonary artery) pressure was calculated
using the modiﬁed Bernoulli equation: PAP = 4 · (tricuspid
systolic jet) 2 + 10 mmHg (estimated right atrial pressure)
[7]. According to Yigla et al. [6] PHT was deﬁned as a systolic
PAP > 35 mmHg. Patients with PHT > 35 mmHg were eval-
uated further by a pulmonologist in order to uncover other po-
tential causes of PHT. This assessment included history,
physical examination, chest radiograph, chest CT, complete
pulmonary function tests, and measurement of arterial blood
gases.
Cardiac output was estimated from the left ventricular out-
ﬂow tract velocity time integral · diameter [8].
(1) Doppler sonography: AVF ﬂow measurement in hemod-
ialysis patients by Doppler ultrasound was done.
Exclusion criteria included
Smokers, any cardiovascular and pulmonary diseases (chronic
obstructive lung disease, chest wall or parenchymal lung dis-
ease) which lead to pulmonary hypertension as well as patients
Prevalence of pulmonary hypertension in patients with chronic kidney disease on and without dialysis 763with chronic coronary heart disease, previous pulmonary
embolism, collagen vascular disease, volume overload at the
time of echocardiography were excluded. All patients provided
written, informed consent.
Statistical analysis
The prevalence of PHT was calculated using the SPSS soft-
ware. Clinical, hemodynamic, and metabolic variables were
compared between patients with and without PHT with ‘‘t’’
test. Values were expressed as mean ± Standard deviation
(SD) and as percentage for categorial parameters. Differences
between groups were compared with Student’s t-test for para-
metric continuous variables. Chi-square test was applied for
estimating the occurrence of categorical variables. Pearson’s
correlation coefﬁcient was used to test the relationship between
PAP and other parameters. A P value <0.05 was used as the
threshold of statistical signiﬁcance.
Results
The most common etiologies of renal failure were diabetes
mellitus and arterial hypertension in all studied groups. Dura-
tion of dialysis treatment was highly statistically signiﬁcant
longer in hemodialysis than peritoneal dialysis group. Our re-
sults showed a highly statistically signiﬁcant decrease in hemo-
globin, hematocrit %, and statistically signiﬁcant increase in
creatinine, phosphorous, SPAP, and EF% in the hemodialysis
group compared to the conservative management group. But
no differences were found between both groups with respect
to age, blood urea, serum HCO3, serum calcium, serum para-
thyroid hormone level or cardiac output. As regards peritoneal
dialysis group, there was a highly statistically signiﬁcant de-
crease in cardiac output, and statistically signiﬁcant increase
in serum calcium, phosphorous compared to the conservative
management group. But, no differences were found between
both groups with respect to age, hemoglobin, hematocrit %,
blood urea, serum HCO3, serum parathyroid hormone level,
SPAP, or EF%. A high prevalence of pulmonary hypertension
(SPAP > 35 mmHg) was demonstrated among 27 patients
(41.53%) receiving long-term hemodialysis; as well as in two
patients (16.66%) receiving peritoneal dialysis, and in ﬁve pa-
tients (22.72%) receiving conservative management. Hemodi-
alysis group has the highest mortality 14 out of 65 patients
(21.54%), then peritoneal dialysis group two patients
(16.66%) (Table 1).
Data on the 27 (out of 65) patients with pulmonary hyper-
tension were compared with the 38 patients without pulmon-
ary hypertension in the hemodialysis group. Diabetes
mellitus and hypertension were the most common etiologies
of renal failure in both subgroups in all studied patients.
Brachial AVF; 23 out of 27 patients (85.18%) represent the
majority of patients in pulmonary hypertension subgroup,
and radial AVF; 23 out of 38 (60.52%) represent the majority
of patients in normal PAP subgroup of hemodialysis patients.
There was a highly statistically signiﬁcant increase in age,
duration of dialysis treatment, serum creatinine, serum phos-
phorous, serum parathyroid hormone, SPAP, cardiac output,
and AVF ﬂow and highly statistically signiﬁcant decrease in
serum HCO3, EF% in pulmonary hypertension subgroup
compared to normal PAP subgroup. But no differences werefound between both subgroups with respect to hemoglobin,
hematocrit %, blood urea, and serum calcium of hemodialysis
patients. Mortality was higher in the pulmonary hypertension
subgroup (11 out of 27 patients (40.74%). As regards perito-
neal dialysis group, there was a highly statistically signiﬁcant
increase in age, duration of dialysis treatment, blood urea, ser-
um creatinine, SPAP, and cardiac output in pulmonary hyper-
tension subgroup compared to normal PAP subgroup. But no
differences were found between both subgroups with respect to
hemoglobin, hematocrit %, serum HCO3, serum calcium, ser-
um phosphorous, serum parathyroid hormone, and EF%.
Data on the 5 (out of 22) patients with pulmonary hyperten-
sion were compared with the 17 patients without pulmonary
hypertension in the conservative management group. There
were highly statistically signiﬁcant increases in blood urea, ser-
um creatinine, serum parathyroid hormone, SPAP, and car-
diac output, and a highly statistically signiﬁcant decrease in
serum HCO3, and serum calcium in the pulmonary hyperten-
sion subgroup compared to the normal PAP subgroup. But no
differences were found between both subgroups with respect to
age, hemoglobin, hematocrit %, serum phosphorous, and
EF% (Table 2).
On comparing data of pulmonary hypertension subgroups
of peritoneal dialysis and conservative management with
hemodialysis subgroup, hematocrit % was statistically signiﬁ-
cantly lower in the hemodialysis subgroup than other both
subgroups. But, serum creatinine, serum phosphorous, SPAP,
and cardiac output were statistically signiﬁcant higher in the
hemodialysis subgroup than both peritoneal dialysis and con-
servative management subgroups (Table 3).
Our results revealed a positive signiﬁcant correlation be-
tween PAP and age, duration of dialysis treatment, blood urea,
serum creatinine, serum phosphorous, serum parathyroid hor-
mone, cardiac output, and AVF ﬂow as well as an inverse cor-
relation between PAP, serum HCO3 and EF% in the
hemodialysis group. A positive signiﬁcant correlation was
found between PAP and age, duration of dialysis treatment,
blood urea, and cardiac output in peritoneal dialysis group.
In the conservative management group there was a positive
signiﬁcant correlation between PAP and blood urea, serum
creatinine, serum parathyroid hormone, and cardiac output
as well as an inverse correlation between PAP, serum HCO3
and serum calcium (Table 4).Discussion
The prevalence of chronic kidney disease (CKD) in the devel-
oped world is 13% and is recognized as a condition that ele-
vates the risk of cardiovascular complications as well as
kidney failure and other complications [9]. End-stage kidney
disease (ESKD) substantially increases the risk of death, car-
diovascular disease, and use of specialized health care [10]. Pul-
monary hypertension (PHT) has been reported to be high
among end-stage renal disease (ESRD) patients [11]. In clinical
practice, shunting of blood from the left to the right side of the
heart and increased cardiac output and pulmonary blood ﬂow
are common medical conditions resulting in PAH [12].
However, Yigla et al. [13] ﬁrst noted unexplained PAH in some
long-term hemodialysis (HD) patients during an epidemiologic
study [13]. Both end-stage renal disease and long-term
hemodialysis via arteriovenous ﬁstula may be involved in the
Table 1 Clinical and laboratory data of studied groups.
Hemodialysis group
(No. = 65)
Peritoneal dialysis
group (No. = 12)
Conservative management
group (No. = 22)
Age (years) 45.72 ± 7.83 P> .05 46.08 ± 3.84 P> .05 45.45 ± 3.77
Sex
Male 34 (52.3%) 7 (58.33%) 13 (59%)
Female 31 (47.7%) 5 (41.67%) 9 (41%)
Etiology of RF
DM 26 (40%) 5 (41.67%) 9 (40.9%)
HTN 19 (29.24%) 4 (33.34%) 8 (36.36%)
Glomerulonephritis 13 (10.86%) 1 (8.32%) 2 (9.1%)
Pyelonephritis 2 (9.1%) 2 (1.66%) 2 (9.1%)
Cystic renal disease 3 (4.61%) 0 1 (4.54%)
Undetermined renal
diagnosis
2 (3.07%) 0 0
Access location of AVF
Brachial 38 (58.46%)
Radial 27 (41.53%)
Duration of dialysis
treatment (months)
80.93 ± 16.96 42.66 ± 13.70 P< 0.001
Hemoglobin (gm/dl) 10.45 ± 1.18 P< 0.001 11.24 ± 1.30 P> 0.05 11.45 ± 1.22
Hematocrit % 29.93 ± 1.75 P< 0.001 33.08 ± 3.11 P> 0.05 34.13 ± 3.41
Blood urea nitrogen (mg/dl) 72.35 ± 12.26 P> 0.05 67.66 ± 17.32 P> 0.05 69.77 ± 17.62
S. creatinine (mg/dl) 3.97 ± 0.82 P< 0.01 3.49 ± 0.79 P> 0.05 3.48 ± 0.57
HCO3 (mEq/L) 21.13 ± 2.12 P> 0.05 21.08 ± 1.56 P> 0.05 21.36 ± 1.36
S. calcium (mg/dl) 8.84 ± 0.46 P> 0.05 9.80 ± 0.80 P< 0.05 9.12 ± 0.90
S. phosphorus (mg/dl) 4.23 ± 0.50 P< 0.05 4.52 ± 0.62 P< 0.01 3.95 ± 0.62
PTH (pg/ml) 242.38 ± 58.17 P> 0.05 233.33 ± 44.69 P> 0.05 248.50 ± 39.07
SPAP> 35 mmHg SPAP
(mmHg)
27 (41.53%) 36.15 ± 13. 24 P< 0.05 2 (16.66%) 27 ± 8.49 P> 0.05 5 (22.72%) 29.72 ± 9.50
EF% 53.53 ± 7.23 P< 0.05 50.08 ± 4.39 P> 0.05 50.40 ± 4.10
Cardiac output (L/min) 5.67 ± 0.78 P> 0.05 5.10 ± 0.46 P< 0.001 5.73 ± 0.51
AVF ﬂow (ml/min.) 463.81 ± 0.78
Outcome
Died 14 (21.54%) 2 (16.66%) 2 (9.09%)
Survivor 51(78.46%) 10 (83.4%) 20 (90.91%)
764 M.M. Emara et al.pathogenesis of pulmonary hypertension by affecting pulmon-
ary vascular resistance and cardiac output. Hormonal and
metabolic derangement associated with end-stage renal disease
might lead to pulmonary arterial vasoconstriction and an in-
crease in pulmonary vascular resistance. Pulmonary arterial
pressure may be further increased by high cardiac output
resulting from the arteriole-venous access itself, worsened by
commonly occurring anemia and ﬂuid overload [14]. On the
other hand, the prevalence of PAH in patients on peritoneal
dialysis (PD) is still a matter of debate [15,16]. Therefore, the
aim of this study was to evaluate the prevalence of primary
pulmonary hypertension (PHT) among chronic kidney disease
patients on and without dialysis and to compare clinical,
hemodynamic, and metabolic variables among patients with
and without PH to search for possible etiologic factors. Our
study demonstrated a high prevalence of pulmonary hyperten-
sion (SPAP > 35 mmHg) among 27 patients (41.53%) receiv-
ing long-term hemodialysis with a mean systolic PAP of
49.33 ± 9.18 mmHg; as well as in two patients (16.66%)
receiving peritoneal dialysis with a mean systolic PAP of
43 ± 1.41 mmHg, and in ﬁve patients (22.72%) receiving con-
servative management with a mean systolic PAP of
44.8 ± 5.89 mmHg. This is in accordance with Domenici
et al., 2010 [17] who reported that Pulmonary hypertension
was found in 23/39 (58.9%) of the HD patients and 2/9(22.2%) of the PD patients; PAP was signiﬁcantly higher in
HD patients than in PD patients (P< 0.01). Also, Patel
et al. [18] demonstrated that forty-one patients had pulmonary
hypertension, of whom 33% were on hemodialysis. Also, Yigla
et al. [19] reported that PH> 35 mmHg was found in 39.7%
of patients receiving hemodialysis (mean ± SD,
44 ± 7 mmHg; range, 37 to 65 mmHg), in none of the patients
receiving PD, and in 1 of 12 predialysis patients. Similarly,
Fabbian et al. [20] demonstrated that PHT (PAP > 35 mmHg)
was detected in 22 patients (39%; PAP 42 ± 6 mmHg) and
was diagnosed in 18.5% of PD patients and 58.6% of HD pa-
tients (P= 0.021). Also, Mahdavi-Mazdeh et al. [21] reported
that prevalence of PHT ranges from 30–40% as detected by
Doppler echocardiography in patients on chronic hemodialysis
(HD) therapy. Abdelwhab and Elshinnawy [11] demonstrated
that PHT was found in 44.4% in group 1 (HD) and in 32.3%
in group 2 (conservative treatment). The most common etiolo-
gies of renal failure were diabetes mellitus and arterial hyper-
tension in all groups and subgroups of our studied patients.
This is similar to the results of the study conducted by Mahd-
avi-Mazdeh et al. [21] who reported that most common etiol-
ogies of renal failure in his studied patients were diabetes
mellitus and arterial hypertension. The present study showed
a highly statistically signiﬁcant increase in age, duration of
dialysis treatment, serum creatinine, serum phosphorous,
Table 2 Clinical and laboratory data of studied groups with and without pulmonary hypertension.
Hemodialysis group (No. = 65) Peritoneal dialysis group (No. = 12) Conservative management Group (No. = 22) Test of signiﬁcance
Normal PAP
(No = 38)
Pulmonary hypertension
(No = 27)
Normal PAP
(No = 10)
Pulmonary hypertension
(No = 2)
Normal PAP
(No = 17)
Pulmonary
hypertension (No = 5)
Age (years) 42.73 ± 8.25 49.92 ± 4.77
P< 0.001
45 ± 3.19 51.5 ± 0.70
P< 0.001
44.70 ± 3.34 48 ± 4.41
P> 0.05
T test
Sex
Male 23(60.52) 11(40.74%) 7(58.33%) 0 12(54.54%) 1(4.54%)
Female 15(39.47%) 16(59.25%) 3 (25%) 2 (16.66%) 5 (22.72%) 4 (18.18%)
Etiology of RF
DM 16(42.10%) 10(37.03%) 4 (40%) 1(50%) 7(41.17%) 2(40%)
HTN 11(28.94%) 9(33.33%) 3 (30%) 1(50%) 6(35.29) 1(20%)
Glomerulo nephritis 7(18.42%) 6(17.6%) 1(10%) 0 1(5.88%) 1(20%)
Pyelonephritis 2(5.26%) 0 2(20%) 0 1(5.88%) 1(20%)0
Cystic renal disease 2(5.26%) 0 0 0 2(11.76%) 0
Undetermined renal diagnosis 0 2(7.40%) 0 0 0
Access location of AVF
Brachial 15(39.47%) 23(85.18%)
Radial 23(60.52%) 4(14.81%)
Duration of dialysis treatment (months) 72.44 ± 14.31 94 ± 10.54
P< 0.001
11.6 ± 2.59 25 ± 1.41
P< 0.001
T test
Hemoglobin gm/dl 10.54 ± 1.29 10.31 ± 1.01
P> 0.05
11.39 ± 1.36 10.50 ± 0.70
P> 0.05
11.64 ± 1.32 10.80 ± 0.44
P> 0.05
T test
Hematocrit % 30.10 ± 1.79 29.70 ± 1.70
P> 0.05
32.50 ± 3.10 36 ± 0
P> 0.05
34.35 ± 3.58 33.4 ± 2.96
P> 0.05
T test
Blood urea (mg/dl) 69.92 ± 10.32 75.77 ± 14.05
P> 0.05
62.10 ± 10.77 98.50 ± 3.53
P< 0.001
63.29 ± 12.50 91.8 ± 14.8
P< 0.001
T test
S. creatinine (mg/dl) 3.60 ± 0.65 4.49 ± 0.77
P< 0.001
3.23 ± 0.55 4.77 ± 0.38
P< 0.004
3.31 ± 0.54 4.02±.25
P< 0.01
T test
HCO3 (mEq/L) 22 ± 1.88 19.92 ± 1.85
P< 0.001
21.40 ± 1.50 19.50 ± 0.70
P> 0.05
21.88 ± 1.05 19.6 ± 0.54
P< 0.001
T test
S. calcium (mg/dl) 8.81 ± 0.54 8.89 ± 0.31
P> 0.05
9.91 ± 0.84 9.25 ± 0.07
P> 0.05
9.34 ± 0.91 8.4 ± 0.35
P< 0.05
T test
S. phosphorus (mg/dl) 3.93 ± 0.26 4.64 ± 0.46
P< 0.001
4.50 ± 0.65 4.65 ± 0.63
P> 0.05
4.05 ± 0.64 3.62 ± 0.43
P> 0.05
T test
PTH (pg/ml) 207.86 ± 41.78 290.96 ± 40.66
P< 0.001
231.10 ± 46.46 244.50 ± 47.37
P> 0.05
236.7 ± 35.72 288.6 ± 17.66
P< 0.006
T test
SPAP (mmHg) 26.78 ± 5.22 49.33 ± 9.18
P< 0.001
23.80 ± 4.44 43 ± 1.41
P< 0.001
25.29 ± 4.25 44.8 ± 5.89
P< 0.001
T test
EF% 56.78 ± 5.83 48.96 ± 6.57
P< 0.001
49.80 ± 4.80 51.50 ± 0.70
P> 0.05
49.94 ± 4.08 52 ± 4.18
P> 0.05
T test
Cardiac output (L/min) 5.14 ± 0.37 6.40 ± 0.58
P< 0.001
4.93 ± 0.26 5.95 ± 0.07
P< 0.001
5.55 ± 0.43 6.34 ± 0.16
P< 0.001
T test
AVF ﬂow (ml/min.) 409.02 ± 74 540.92 ± 58.04
P< 0.001
T test
Outcome
Died 3(7.98%) 11(40.74%) 1(10%) 1(50%) 1(5.88%) 1(20%) Chi-square
Survivor 35(92.10%) 16(59.25%)
v2 = 8.693b
P= 0.003
9(90%) 1(50%)
v2 = 1.920a
P= 0.166 NS
16(72.72%) 4(80%)
v2 = 0.647b
P= 0.421 NS
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Table 3 Clinical and laboratory data of pulmonary hypertension subgroups in all studied patients.
Conservative management group (No. = 5) Peritoneal dialysis group (No. = 2) Hemodialysis group (No. = 27)
Age 48 ± 4.41 P> 0.05 51.50 ± 0.70 P> 0.05 49.92 ± 4.77
Duration of dialysis 25 ± 1.41 P< 0.001 94 ± 10.54
Hemoglobin (gm/dl) 10.80 ± 0.44 P> 0.05 10.50 ± 0.70 P> 0.05 10.31 ± 1.01
Hematocrit (%) 33.40 ± 2.96 P< 0.05 36 ± 0 P< 0.001 29.70 ± 1.70
Blood urea (mg/dl) 91.80 ± 14.8 P< 0.05 98.50 ± 3.53 P< 0.001 75.77 ± 14.05
S. creatinine (mg/dl) 4.02 ± 0.25 P< 0.05 4.77 ± 0.38 P> 0.05 4.49 ± 0.77
HCO3 (mEq/L) 19.60 ± 0.54 P> .05 19.50 ± 0.70 P> 0.05 19.92 ± 1.85
S. calcium (mg/dl) 8.40 ± 0.35 P> 0.05 9.25 ± 0.07 P> 0.05 8.89 ± 0.31
S. phosphorus (mg/dl) 3.62 ± 0.43 P< 0.001 4.65 ± 0.63 P> 0.05 4.64 ± 0.46
PTH (pg/ml) 288.6 ± 17.6 P> 0.05 244.50 ± 47.37 P> 0.05 290.96 ± 40.66
SPAP (mmHg) 44.80 ± 5.89 P> 0.05 43 ± 1.41 P< 0.001 49.33 ± 9.18
EF% 52 ± 4.18 P> 0.05 51.50 ± 0.70 P> 0.05 48.96 ± 6.57
Cardiac output (L/min) 6.34 ± 0.16 P> 0.05 5.95 ± 0.07 P< 0.001 6.40 ± 0.58
Outcome
Died 1(20%) 1(50%) 11(40.74%)
Survivor 4(80%) 1(50%) 16(59.25%)
Table 4 Correlations between pulmonary arterial pressure (PAP) and different variables in all studied groups.
Hemodialysis group (No. = 65) Peritoneal dialysis group (No. = 12) Conservative management group (No. = 22)
Pearson correlation Signiﬁcance Pearson correlation Signiﬁcance Pearson correlation Signiﬁcance
Age 0.431 P< 0.001 0.726 P< 0.008 0.339 P> 0.05
Duration of dialysis 0.536 P< 0.001 0.780 P< 0.003
Hemoglobin (gm/dl) 0.127 P> 0.05 0.092 P> 0.05 0.214 P> 0.05
Hematocrit (%) 0.187 P> 0.05 0.374 P> 0.05 0.003 P> 0.05
Blood urea mg/dl 0.339 P< 0.006 0.643 P< 0.02 0.630 P< 0.002
S. creatinine (mg/dl) 0.433 P< 0.001 0.553 P> 0.05 0.553 P< 0.008
HCO3 (mEq/L) 0.464 P< 0.001 0.404 P> 0.05 0.623 P< 0.002
S. calcium (mg/dl) 0.086 P> 0.05 0.422 P> 0.05 0.462 P< 0.03
S. phosphorus (mg/dl) 0.584 P< 0.001 0.144 P> 0.05 0.247 P> 0.05
PTH (pg/ml) 0.577 P< 0.001 0.223 P> 0.05 0.656 P< 0.001
EF% 0.369 P< 0.002 0.124 P> 0.05 0.046 P> 0.05
Cardiac output (L/min) 0.749 P< 0.001 0.757 P< 0.004 0.706 P< 0.001
AVF ﬂow (ml/min.) 0.809 P< 0.001
766 M.M. Emara et al.serum parathyroid hormone, SPAP, cardiac output, and AVF
ﬂow and highly statistically signiﬁcant decrease in serum
HCO3, EF% in pulmonary hypertension subgroup compared
to normal PAP subgroup in the hemodialysis patients and a
positive signiﬁcant correlation between PAP and age, duration
of dialysis treatment, blood urea, serum creatinine, serum
phosphorous, serum parathyroid hormone, cardiac output,
and AVF ﬂow as well as an inverse correlation between
PAP, serum HCO3 and EF%. Diabetes mellitus and hyperten-
sion have a higher prevalence in the pulmonary hypertension
subgroup than the normal PAP subgroup. In a similar study
Havlucu et al. [4] evaluated 23 predialysis and 25 HD patients,
those with elevated PAP had increased PTH levels, cardiac
output values and chronic renal failure duration; AVF ﬂow
and duration were positively and residual urine volume nega-
tively correlated with PAP. Yigla et al. [19] reported that pa-
tients with PH receiving hemodialysis had a signiﬁcantly
higher cardiac output (6.9 L/min vs 5.5 L/min, p= 0.017).
Abdelwhab and Elshinnawy [11] demonstrated that Patients
with PHT in the hemodialysis group have a signiﬁcantly higher
AVF blood ﬂow and PAP correlates with AVF ﬂow. Fabbian
et al. [20] demonstrated that the group of subjects with PH hadhigher dialysis vintage (63 ± 60 versus 27 ± 32 months,
P= 0.016), interdialytic weight gain (2.1 ± 1 versus
1.3 ± 0.9 kg, P= 0.016), lower diastolic blood pressure
(73 ± 12 versus 80 ± 8 mmHg, P= 0.01) and ejection frac-
tion (54 ± 13 versus 60 ± 7%, P= 0.021) than the patients
with normal PAP. PAP was correlated positively with diastolic
left ventricular volume (P= 0.32, P= 0.013) and negatively
with ejection fraction (r= 0.54, P< 0.001). In the same
group they found a higher prevalence of diabetes (18 versus
3%, P= 0.05). Abdallah et al. [22] demonstrated that PHT
(systolic PAP = 35 mmHg) was observed in 25 (56.8%) pa-
tients receiving hemodialysis with a mean systolic PAP of
46.4 ± 13.6 mmHg. In the predialysis group after creation of
AV ﬁstula, PHT was found in 6 (42.9%) patients with a mean
systolic PAP of 42.8 ± 12.8 mmHg. The cardiac output and
AV shunt ﬂow were found to be increased in patients with ele-
vated systolic PAP in both groups (p< 0.05). CRF duration
and AV ﬁstula duration were positively correlated with systolic
PAP in patients receiving hemodialysis (p< 0.05). On the
other hand, Amin et al. [23] reported that there was no signif-
icant difference between patients with PH and those without
PH in end-stage renal disease patients, who were receiving
Prevalence of pulmonary hypertension in patients with chronic kidney disease on and without dialysis 767regular hemodialysis with regard to age, duration of dialysis,
serum calcium (9.6 ± 2 mg/dL vs 10 ± 2 mg/dL), phosphorus
(6 ± 1.4 mg/L vs 6.2 ± 1.9 mg/L), alkaline phosphatase
(609 ± 768 U/L vs 473 ± 574 U/L), parathyroid hormone
(PTH) [420 ± 512 pg/mL vs 354 ± 519 pg/mL]. Mortality in
our studied hemodialysis group was higher in the pulmonary
hypertension subgroup (11 out of 27 patients (40.74%). Yigla
et al., 2003 [19] reported that nine patients (15.5%) died during
follow-up: six patients with PH and three patients without PH,
corresponding to mortality rates of 30.4% and 8.5%, respec-
tively in his studied patients receiving hemodialysis and perito-
neal dialysis. Yigla et al. [6] demonstrated that patients with
PHT evaluated by echocardiography at the beginning of HD
treatment, and with PHT developing soon after HD initiation,
had shorter survival than their counterparts without PHT. Our
study showed a highly statistically signiﬁcant increase in age,
duration of dialysis treatment, blood urea, serum creatinine,
SPAP, and cardiac output in pulmonary hypertension sub-
group compared to normal PAP subgroup of peritoneal dialy-
sis group and a positive signiﬁcant correlation between PAP
and age, duration of dialysis treatment, blood urea, and car-
diac output. Etemadi et al. [24] showed no differences in gen-
der, age, weight, duration of dialysis, calcium, phosphorus,
alkaline phosphatase, albumin, parathyroid hormone level, to-
tal iron binding capacity, ferritin, creatinine and blood urea
nitrogen between the patients with PAH and those with nor-
mal PAP (P> 0.05) in the peritoneal dialysis group. Fabbian
et al. [20] demonstrated that PD patients with PHT had lower
ejection fraction (45 ± 15 versus 62 ± 5%, P= 0.003) than
those without PHT. PAP was positively correlated with dia-
stolic left ventricular volume (r= 0.32, P= 0.013) and nega-
tively with ejection fraction (r= 0.54, P< 0.001).
Hematocrit % was statistically signiﬁcantly lower and cardiac
output statistically signiﬁcantly higher in the hemodialysis pul-
monary hypertension subgroup than both peritoneal dialysis
and conservative management subgroups. Yigla et al. [19]
compared data on the 23 patients with PH receiving hemodial-
ysis with the 35 patients without PH receiving hemodialysis.
The cardiac output was signiﬁcantly higher among the PH sub-
group (6.9 ± 1.8 L/min vs 5.5 ± 0.7 L/min, p< 0.017). The
hemoglobin and hematocrit levels were signiﬁcantly lower in
the PH subgroup (9.7 ± 1 g/dL vs 10.9 ± 1.1 g/dL and
30.4 ± 2.1% vs 34.6 ± 2.5%, p= 0.012 and 0.007, respec-
tively). Nissenson et al. [25] has recommended optimization
of the hematocrit to maximize the blood oxygen carrying
capacity and minimize the impact of arterial hypoxemia. It
has been found that repeated episodes of hypoxia during
and/or after HD lead to the development of pulmonary hyper-
tension and cause morphological changes in the lung [26–28].
In the present study, the prevalence of pulmonary hyperten-
sion was highest in the HD group (41.53%), which is not sur-
prising, as these patients had higher AV ﬁstula ﬂow, cardiac
output, serum creatinine, and phosphorous levels; lower hemo-
globin, hematocrit, serum bicarbonate values, and EF%. Bra-
chial AVF; 23 out of 27 patients (85.18%) represent the
majority of patients in the pulmonary hypertension subgroup,
and radial AVF; 23 out of 38 (60.52%) represent the majority
of patients in the normal PAP subgroup of our studied hemod-
ialysis patients. It has been suggested that some factors, such
as the size or the location of AVF, are involved in the mecha-
nism that increases PAP [4]. On the contrary Tarrass et al. [29]
did not ﬁnd any difference in cardiac output between patientswith and without PHT, and the effect of AVF location was not
statistically signiﬁcant. Beigi et al. [30] reported a positive cor-
relation between mean ﬁstula ﬂow and PAP and as well as in
our study, an inverse correlation between PAP and ejection
fraction.
Study limitations
This study has certain limitations. The exclusion criteria used
in our protocol resulted in a small study group, since the
majority of patients with CKD had concomitant cardiac or
pulmonary disease. The exclusion of patients with CKD with
cardiac or pulmonary disease from analysis was a methodolog-
ical necessity. Moreover, PAP was measured by a non-invasive
method, Doppler echocardiography, with-out obtaining direct
invasive measurements (e.g. right heart catheterization). How-
ever, measurements of PAP by the applied Doppler echocar-
diographic method have been reported to have a good
correlation with measurements obtained by invasive methods
in some studies [24,31,32]. This method of PAP measurement
has been widely applied in previous studies on PAH in patients
on HD or PD [2,5,19,21].
Conclusion
This study demonstrated a high prevalence of pulmonary
hypertension among patients with CKD on and without dial-
ysis. The prevalence was highest among patients with ESRD
receiving long-term hemodialysis (41.53%) than those on per-
itoneal dialysis especially in patients with older age, longer
duration of dialysis treatment, higher AV ﬁstula ﬂow, cardiac
output, serum creatinine; lower hemoglobin, hematocrit, ser-
um bicarbonate values, and EF% which all positively corre-
lated with PAP and may be involved in the pathogenesis of
pulmonary hypertension. Early detection of pulmonary hyper-
tension is important in order to avoid the serious consequences
of the disease, changing dialysis modality or referring for renal
transplantation. Patients on peritoneal dialysis (PD) had the
least prevalence of pulmonary hypertension 2/12(16.66%).
Hence, it seems that PD may be better as the mode of renal
replacement therapy if development of pulmonary hyperten-
sion is to be prevented.
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